Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Pili

Showing results (1-10 of 223) with videos related to

Pageof 23
Sort By:
Oncology (Williston Park, N.Y.)|February 8, 2011
Is this a true renaissance for the treatment of prostate cancer?Roberto Pili
Clinical Advances in Hematology & Oncology : H&O|June 13, 2009
Recent investigations of histone deacetylase inhibitors in renal cell carcinomaRoberto Pili
Pharmaceuticals (Basel, Switzerland)|December 15, 2010
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesLeigh Ellis, Roberto Pili
Aging|October 27, 2016
Genomic profiling of collecting duct renal carcinomaSreenivasulu Chintala, Roberto Pili
Current Oncology Reports|January 22, 2013
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancerSaby George, Roberto Pili
Oncoimmunology|November 20, 2012
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapyLi Shen, Roberto Pili
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinomaSwathi Ramakrishnan, Roberto Pili
Nature Reviews. Endocrinology|May 17, 2018
Low-protein diet in cancer: ready for prime time?Roberto Pili, Luigi Fontana
Expert Review of Vaccines|August 23, 2011
Provenge: combating prostate cancer with a vengeance?Thomas Schwaab, Roberto Pili
Expert Review of Anticancer Therapy|December 4, 2009
Update on novel agents in renal cell carcinomaIla Tamaskar, Roberto Pili
Pageof 23

Showing results (1-10 of 223) with videos related to

Sort By:
Pageof 23
Oncology (Williston Park, N.Y.)|February 8, 2011
Is this a true renaissance for the treatment of prostate cancer?Roberto Pili
Clinical Advances in Hematology & Oncology : H&O|June 13, 2009
Recent investigations of histone deacetylase inhibitors in renal cell carcinomaRoberto Pili
Pharmaceuticals (Basel, Switzerland)|December 15, 2010
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesLeigh Ellis, Roberto Pili
Aging|October 27, 2016
Genomic profiling of collecting duct renal carcinomaSreenivasulu Chintala, Roberto Pili
Current Oncology Reports|January 22, 2013
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancerSaby George, Roberto Pili
Oncoimmunology|November 20, 2012
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapyLi Shen, Roberto Pili
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinomaSwathi Ramakrishnan, Roberto Pili
Nature Reviews. Endocrinology|May 17, 2018
Low-protein diet in cancer: ready for prime time?Roberto Pili, Luigi Fontana
Expert Review of Vaccines|August 23, 2011
Provenge: combating prostate cancer with a vengeance?Thomas Schwaab, Roberto Pili
Expert Review of Anticancer Therapy|December 4, 2009
Update on novel agents in renal cell carcinomaIla Tamaskar, Roberto Pili
Pageof 23